Oyagen, Inc. Publishes Study On Its OYA1 As A "Highly Effective" Experimental Drug Candidate For Treating Infections By The Ebola Virus
Share this article Share this article ROCHESTER, N.Y., Jan. 7, 2021 /PRNewswire/ -- OyaGen, Inc. announced today publication in VIRUSES, a peer reviewed journal, of studies carried out by OyaGen in collaboration with NIH/NIAID Integrated Research Facility at Fort Detrick MD. This Study identified OYA1 as a "highly effective" antiviral against several viruses including Ebola and Lassa viruses. Bennett et al., A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.' (2021) About OYA1. OYA1 (a.k.a. sangivamycin) has broad-spectru...